188 related articles for article (PubMed ID: 8896492)
1. The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women.
Carter JJ; Koutsky LA; Wipf GC; Christensen ND; Lee SK; Kuypers J; Kiviat N; Galloway DA
J Infect Dis; 1996 Nov; 174(5):927-36. PubMed ID: 8896492
[TBL] [Abstract][Full Text] [Related]
2. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection.
Carter JJ; Koutsky LA; Hughes JP; Lee SK; Kuypers J; Kiviat N; Galloway DA
J Infect Dis; 2000 Jun; 181(6):1911-9. PubMed ID: 10837170
[TBL] [Abstract][Full Text] [Related]
3. A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16.
Kirnbauer R; Hubbert NL; Wheeler CM; Becker TM; Lowy DR; Schiller JT
J Natl Cancer Inst; 1994 Apr; 86(7):494-9. PubMed ID: 8133532
[TBL] [Abstract][Full Text] [Related]
4. Seroprevalence of human papillomavirus types 6 and 16 capsid antibodies in homosexual men.
Hagensee ME; Kiviat N; Critchlow CW; Hawes SE; Kuypers J; Holte S; Galloway DA
J Infect Dis; 1997 Sep; 176(3):625-31. PubMed ID: 9291307
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of antibodies to human papillomavirus (HPV) type 16 virus-like particles in relation to cervical HPV infection among college women.
Viscidi RP; Kotloff KL; Clayman B; Russ K; Shapiro S; Shah KV
Clin Diagn Lab Immunol; 1997 Mar; 4(2):122-6. PubMed ID: 9067643
[TBL] [Abstract][Full Text] [Related]
6. Serologic response to human oncogenic papillomavirus types 16, 18, 31, 33, 39, 58 and 59 virus-like particles in colombian women with invasive cervical cancer.
Combita AL; Bravo MM; Touzé A; Orozco O; Coursaget P
Int J Cancer; 2002 Feb; 97(6):796-803. PubMed ID: 11857357
[TBL] [Abstract][Full Text] [Related]
7. Specific serum IgG, IgM and IgA antibodies to human papillomavirus types 6, 11, 16, 18 and 31 virus-like particles in human immunodeficiency virus-seropositive women.
Petter A; Heim K; Guger M; Ciresa-Kö Nig A; Christensen N; Sarcletti M; Wieland U; Pfister H; Zangerle R; Höpfl R
J Gen Virol; 2000 Mar; 81(Pt 3):701-8. PubMed ID: 10675407
[TBL] [Abstract][Full Text] [Related]
8. Mucosal immunoglobulin-A and -G responses to oncogenic human papilloma virus capsids.
Sasagawa T; Rose RC; Azar KK; Sakai A; Inoue M
Int J Cancer; 2003 Apr; 104(3):328-35. PubMed ID: 12569556
[TBL] [Abstract][Full Text] [Related]
9. Human papillomavirus 16 and 18 L1 serology compared across anogenital cancer sites.
Carter JJ; Madeleine MM; Shera K; Schwartz SM; Cushing-Haugen KL; Wipf GC; Porter P; Daling JR; McDougall JK; Galloway DA
Cancer Res; 2001 Mar; 61(5):1934-40. PubMed ID: 11280749
[TBL] [Abstract][Full Text] [Related]
10. Cervical mucus antibodies against human papillomavirus type 16, 18, and 33 capsids in relation to presence of viral DNA.
Wang Z; Hansson BG; Forslund O; Dillner L; Sapp M; Schiller JT; Bjerre B; Dillner J
J Clin Microbiol; 1996 Dec; 34(12):3056-62. PubMed ID: 8940448
[TBL] [Abstract][Full Text] [Related]
11. Characterization of IgA response among women with incident HPV 16 infection.
Onda T; Carter JJ; Koutsky LA; Hughes JP; Lee SK; Kuypers J; Kiviat N; Galloway DA
Virology; 2003 Jul; 312(1):213-21. PubMed ID: 12890634
[TBL] [Abstract][Full Text] [Related]
12. Seroreactivity to HPV16 virus-like particles as a marker for cervical cancer risk in high-risk populations.
Nonnenmacher B; Kruger Kjaer S; Svare EI; Scott JD; Hubbert NL; van den Brule AJ; Kirnbauer R; Walboomers JM; Lowy DR; Schiller JT
Int J Cancer; 1996 Dec; 68(6):704-9. PubMed ID: 8980170
[TBL] [Abstract][Full Text] [Related]
13. Detection of cervical antibodies to human papillomavirus type 16 (HPV-16) capsid antigens in relation to detection of HPV-16 DNA and cervical lesions.
Hagensee ME; Koutsky LA; Lee SK; Grubert T; Kuypers J; Kiviat NB; Galloway DA
J Infect Dis; 2000 Apr; 181(4):1234-9. PubMed ID: 10753726
[TBL] [Abstract][Full Text] [Related]
14. Human papillomavirus antibody responses among patients with incident cervical carcinoma.
Wang Z; Konya J; Avall-Lundkvist E; Sapp M; Dillner J; Dillner L
J Med Virol; 1997 Aug; 52(4):436-40. PubMed ID: 9260694
[TBL] [Abstract][Full Text] [Related]
15. Serological responses to human papillomavirus type 6 and 16 virus-like particles in patients with cervical neoplastic lesions.
Sasagawa T; Inoue M; Lehtinen M; Zhang W; Gschmeissner SE; Hajibagheri MA; Finch J; Crawford L
Clin Diagn Lab Immunol; 1996 Jul; 3(4):403-10. PubMed ID: 8807204
[TBL] [Abstract][Full Text] [Related]
16. Immune activation in cervical neoplasia: cross-sectional association between plasma soluble interleukin 2 receptor levels and disease.
Hildesheim A; Schiffman MH; Tsukui T; Swanson CA; Lucci J; Scott DR; Glass AG; Rush BB; Lorincz AT; Corrigan A; Burk RD; Helgesen K; Houghten RA; Sherman ME; Kurman RJ; Berzofsky JA; Kramer TR
Cancer Epidemiol Biomarkers Prev; 1997 Oct; 6(10):807-13. PubMed ID: 9332763
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal study of patients after surgical treatment for cervical lesions: detection of HPV DNA and prevalence of HPV-specific antibodies.
Tachezy R; Mikysková I; Ludvíková V; Rob L; Kucera T; Slavík V; Beková A; Robová H; Pluta M; Hamsíková E
Eur J Clin Microbiol Infect Dis; 2006 Aug; 25(8):492-500. PubMed ID: 16896828
[TBL] [Abstract][Full Text] [Related]
18. A survey of seroprevalence of human papillomavirus types 16, 18 and 33 among children.
af Geijersstam V; Eklund C; Wang Z; Sapp M; Schiller JT; Dillner J; Dillner L
Int J Cancer; 1999 Feb; 80(4):489-93. PubMed ID: 9935145
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of seroreactivity to human papillomavirus type 16 virus-like particles in an incident case-control study of cervical neoplasia.
Wideroff L; Schiffman MH; Nonnenmacher B; Hubbert N; Kirnbauer R; Greer CE; Lowy D; Lorincz AT; Manos MM; Glass AG
J Infect Dis; 1995 Dec; 172(6):1425-30. PubMed ID: 7594698
[TBL] [Abstract][Full Text] [Related]
20. Serologic response to human papillomavirus type 16 (HPV-16) virus-like particles in HPV-16 DNA-positive invasive cervical cancer and cervical intraepithelial neoplasia grade III patients and controls from Colombia and Spain.
Nonnenmacher B; Hubbert NL; Kirnbauer R; Shah KV; Muñoz N; Bosch FX; de Sanjosé S; Viscidi R; Lowy DR; Schiller JT
J Infect Dis; 1995 Jul; 172(1):19-24. PubMed ID: 7797910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
